SCHEMBL769876

SCHEMBL769876

CCCc1nc2cc(NCc3ccc(CC)cc3)ccc2n1-c1ccc(OCC)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.60
KDM4E B2RXH2 8/20 0.60
ALDH1A1 P00352 6/20 0.60
HSD17B10 Q99714 5/20 0.60
HPGD P15428 3/20 0.55
GAA P10253 5/20 0.53
NPC1 O15118 9/20 0.48
RAB9A P51151 9/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
ALOX15 P16050 2/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
TP53 P04637 3/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
APP P05067 1/20 0.46
ALOX12 P18054 1/20 0.46
MAPK1 P28482 1/20 0.46
SNCA P37840 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769888 0.87 MAPT (0.72) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL770119 0.86 MAPT (0.62) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL769069 0.83 MAPT (0.59) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL770102 0.78 MAPT (0.70) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL2067352 0.77 MAPT (0.59) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL15201462 0.75 MAPT (0.57) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL15201373 0.72 MAPT (0.60) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL14463784 0.72 TP53 (0.46) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL4928429 0.71 NPC1 (0.53) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL769848 0.71 MAPT (0.69) MAPTKDM4EALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US claimed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection ZC3HAV1, GZMB, GTF3C3 MAPT 2844/4885KDM4E 1661/4885ALDH1A1 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.